Risk for type 2 diabetes significantly reduced at walking speed of 4 km/hour and greater based on dose-response analysis

Estrogen gender-affirming hormone therapy may be a risk factor

Food insecurity, housing insecurity, mental health concerns, and the perceived importance of practitioner concordance all pose barriers

Positive treatment effect on general health score seen after 18 months persisted during five-year follow-up

Mean hematocrit ranged from 41.84 to 45.68 percent for those receiving testosterone as gender-affirming hormone therapy

In age-stratified analyses, veterans aged 75 to 85 years had higher mortality in association with unstable housing

Strategies include filing patents after FDA approval and obtaining large numbers of patents on delivery devices

Higher-income adults had increase in diabetes and obesity, but no change in hypertension

Fasting insulin and HOMA-IR values were increased with sleep restriction versus maintenance of adequate sleep

Arginine-stimulated copeptin inferior for diagnosing arginine vasopressin deficiency, but patients prefer arginine testing